L
Ligand Pharmaceuticals Incorporated (LGND)
NGM – Real Time Price. Currency in USD
222.00
+1.52 (0.69%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
222.00
+1.52 (0.69%)
At close: May 12, 2026, 4:00 PM EDT
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
| Name | Position |
|---|---|
| Dr. Karen R. Reeves M.D. | Senior VP of Investments & Head of Clinical Strategy |
| Dr. Keith Marschke Ph.D. | Senior Vice President of Biology & Scientific Affairs |
| Dr. Vincent D. Antle Ph.D. | Senior Vice President of Technical Operations & QA - Capitsol |
| Mr. Andrew T. Reardon J.D. | Chief Legal Officer & Secretary |
| Mr. Octavio Espinoza | Chief Financial Officer |
| Mr. Paul J. Hadden | Senior Vice President of Investments & Business Development |
| Mr. Richard B. Baxter | Senior VP of Investment Operations |
| Mr. Scott M. Plesha | CEO of Pelthos Therapeutics |
| Mr. Todd C. Davis Ph.D. | CEO & Director |
| Ms. Melanie J. Herman CPA | Executive Director of Investor Relations and Financial Planning & Analysis |
| Date | Type | Document |
|---|---|---|
| 2026-05-08 | 10-Q | lgnd-20260331.htm |
| 2026-05-07 | 8-K | lgnd-20260507.htm |
| 2026-04-30 | 8-K | lgnd-20260424.htm |
| 2026-04-27 | DEFA14A | d143046ddefa14a.htm |
| 2026-04-27 | 8-K | d143046d8k.htm |
| 2026-04-21 | DEFA14A | ligand-2026proxysupplement.htm |
| 2026-02-27 | S-3ASR | d86418ds3asr.htm |
| 2026-02-26 | 8-K | lgnd-20260226.htm |
| 2025-12-18 | 8-K | d938301d8k.htm |
| 2025-11-07 | 10-Q | lgnd-20250930.htm |